“The company's wholly-owned subsidiary, Ipca Pharmaceuticals Inc, USA, has acquired, on 2 October, 2018, 80 per cent share capital of Bayshore Pharmaceuticals LLC, a New Jersey limited liability company @ $10.286 millions,” Ipca Labs informed stock exchanges in a statement.
Bayshore had reported a total income of $7.05 million and earnings before interest, depreciation tax and amortisation (Ebidta) of $0.56 million, for the year ended December 31, 2017.
The acquisition of a majority stake in Bayshore will allow the company to commercialise its registered generic drug products in the US market.
No comments:
Post a Comment